CAMBRIDGE, England, June 14, 2011 /CNW/ - Arecor and GSK have entered
into a license agreement to develop advanced formulations of vaccines
combining Arecor's unique formulation technologies with GSK's
proprietary vaccines. GSK and Arecor have collaborated to develop new
approaches which could offer significant improvements to the
administration of several vaccines in development. In return for the
license to their technology, Arecor will receive payments on relevant
development milestones and royalties on sales.
Tom Saylor, CEO of Arecor, stated, "Arecor is pleased to work closely
with one of the global leaders in vaccine products and technology. The
relationship with GSK offers Arecor the potential to apply its
broad-ranging expertise in biomolecule stabilisation to specific
projects with GSK."
Arecor Limited was established to provide formulation solutions to
pharmaceutical and biotech companies developing proteins, vaccines and
diagnostics based upon new insights into stabilization of biologics.
Proteins and vaccines are often fragile entities, and stability can
represent significant constraints in the development of new products
and extending the use of existing products. Arecor has developed
Arestat™, a patented set of tools for stabilization which address the
main pathways of degradation. As a simple reformulation, Arestat™ can
be readily incorporated into standard manufacturing practice, without
covalent modification of the biologic and using excipients approved for
the route of delivery. Arecor currently has active feasibility programs
and licenses with many of the top pharmaceutical and biotech companies
on a wide range of proteins and vaccines.
For further information:
Tom Saylor, CEO email@example.com
2 Cambridge Science Park